EUCTR2011-004810-41-AT进行中（未招募）不适用
An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C. - TRICO
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Treatment-naïve adult women and men with chronic hepatitis C monoinfection, genotype 1 and compensated liver disease including cirrhosis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 142
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •- Women with ongoing pregnancy or breast feeding
- •- Male partners of women who are pregnant
研究者
相似试验
进行中（未招募）
不适用
An international, multicenter study evaluating cure rate and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in previously untreated patients with genotype 1 chronic hepatitis C.Genotype 1 CHC virus infectionMedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-004810-41-ESF. Hoffmann-La Roche Ltd150
进行中（未招募）
不适用
An international, multicenter study evaluating cure rate and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in previously untreated patients with genotype 1 chronic hepatitis C.EUCTR2011-004810-41-HUF. Hoffmann-La Roche Ltd150
进行中（未招募）
不适用
An international, multicenter study evaluating cure rate and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in previously untreated patients with genotype 1 chronic hepatitis C.EUCTR2011-004810-41-PLF. Hoffmann-La Roche Ltd150
进行中（未招募）
不适用
An international, multicenter study evaluating cure rate and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in previously untreated patients with genotype 1 chronic hepatitis C.Genotype 1 CHC virus infectionMedDRA version: 16.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-004810-41-DEF. Hoffmann-La Roche Ltd150
已完成
2 期
An international, multicentre, open-label study to evaluate the efficacy and safety of two different vaccination regimens of immunotherapy with allogeneic dendritic cells, DCP-001, in patients with acute myeloid leukemia that are in remission with persistent MRD.Blood cancer10024324Acute Myeloid LeukemiaNL-OMON52641Immunicum AB (voorheen DCprime bv)1